Monday Plenary Keynote Session is Included in All Premium and Standard Registration Packages






TRACK KEYNOTES (TUESDAY - THURSDAY)

Synergistic Effect of Hydrodynamic Flow and Interfaces on Antibody Aggregation

Paolo Arosio, PhD, Assistant Professor, Chemistry & Applied Biosciences, ETH Zurich

Novel Cytokine-Grafting Technique Generates Potent Interleukin-2 Immunotherapy with Efficacy in Multiple Cancer Models

Onur Boyman, Professor & Chair, Immunology, University Hospital Zurich

ATMP Potency: Metrological Considerations

Christopher Bravery, PhD, Consulting Regulatory Scientist, Consulting on Advanced Biologicals Ltd.

Rapid and Nimble Expression and Production Tools: Lessons Learned over the Past Few Months

Nicola A. Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium


Immunologic Mechanisms and Engineering Objectives: Case Study of Anti-PD-L1 x IL-15
Daniel S. Chen, MD, PhD, CMO, IGM Biosciences

Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?
Daniel S. Chen, MD, PhD, CMO, IGM Biosciences

Antibody Discovery Is More than Just Binders

Ruud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKline

How Stroma Targeting through a Novel FAP-Targeting ADC, OMTX705, Represents a New Treatment Alternative for Chemotherapy and Pembrolizumab-Resistant Solid Tumors

Myriam Fabre, PhD, CSO, Oncomatryx Biopharma SL

Highly Targeted Anticalin® Therapies

Hitto Kaufmann, PhD, CSO & Senior Vice President, Pieris Pharmaceuticals GmbH

Immunocytokines with “Activity on Demand”

Dario Neri, PhD, Full Professor, Chemistry & Applied Biosciences, ETH Zurich

Next-Generation T Cell Engagers

Paul Parren, PhD, Executive Vice President & Head, Lava Therapeutics

Why We Develop Autoimmune Diseases: Hyperstimulation of the Immune System

Yehuda Shoenfeld, MD, FRCP, MaACR, Past Incumbent of the Laura Schwarz-Kipp Chair, Research of Autoimmune Diseases, Tel-Aviv University

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Éric Vivier, PhD, CSO, Innate Pharma

david-woodEvaluating a New Technology in the Context of Historical Successes and Failures: A Case Study on Self- Cleaving Tags

David W. Wood, PhD, Professor, Chemical & Biomolecular Engineering, The Ohio State University